Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249763 | 0.90 | HDAC8 (0.50) | HDAC8HDAC6HDAC1SMPD1 | |
| SCHEMBL356187 | 0.86 | HDAC8 (0.55) | HDAC8HDAC6HDAC1SMPD1 | |
| SCHEMBL354763 | 0.86 | NPC1 (0.44) | HDAC8NPC1RAB9A | |
| SCHEMBL10247110 | 0.78 | HDAC8 (0.48) | HDAC8HDAC6HDAC1 | |
| SCHEMBL353154 | 0.77 | CHRNB2 (0.44) | NPC1RAB9A | |
| SCHEMBL10247051 | 0.76 | HDAC8 (0.48) | HDAC8HDAC6HDAC1SMPD1MCHR1 | |
| SCHEMBL10247303 | 0.74 | HDAC8 (0.53) | HDAC8HDAC6NPC1RAB9A | |
| SCHEMBL10247197 | 0.74 | HDAC8 (0.53) | HDAC8HDAC6HDAC1 | |
| SCHEMBL10249808 | 0.72 | HDAC8 (0.53) | HDAC8HDAC6HDAC1SMPD1 | |
| SCHEMBL355731 | 0.72 | CHRNB2 (0.44) | HDAC8HDAC6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | HDAC8 13/4885HDAC6 1/4885HDAC1 2/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC8 20/4885HDAC6 1/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.